第三代抗癫痫新药呲仑帕奈已经在中国上市

Epilepsy is a chronic non-communicable disease of the brain that affects approximately 50 million people worldwide, making it one of the most common neurological diseases worldwide. Perampanel is an innovative anti-epileptic drug that is taken orally once daily. It is a highly selective, non-competitive AMPA-type receptor antagonist. Perampanel can reduce the over-excitability of nerves associated with epileptic seizures by targeting the glutamate activity of postsynaptic membrane AMPA receptors. On September 29, 2019, the State Food and Drug Administration approved the drug import license (perampanel), which means that China’s epilepsy treatment field officially welcomed the first non-competitive AMPA receptor antagonist. Perampanel (perampanel) will bring new treatment methods and means to the majority of epilepsy patients and their families.

A multi-center randomized double-blind placebo-controlled clinical phase III trial has confirmed that perampanel (perampanel) as adjuvant therapy can reduce focal seizures by 23.3%-27.2%. Another clinical phase III trial showed that perampanel could reduce generalized tonic-clonic seizures by 76.5%, compared with 38.4% in the placebo group. In addition, the 13-week seizure-free rate of patients in the perampanel group was 30.9%, which was much higher than the 12.3% in the placebo group. From the above test data, it can be seen that perampanel has a significant therapeutic effect. This drug can reduce focal attacks, relieve patients' pain, improve patients' quality of life, and can have a positive effect on the patient's condition. The launch of this drug has brought new treatment options to many epilepsy patients.

The above is an introduction to perampanel. If patients want to know more drug information about perampanel (such as drug prices, purchase channels, etc.), they can consult the medical companion travel service.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles: